Early pipeline planning and assessments
As potential treatments begin their journey through clinical development programs, a range of decisions need to be made, many of which can ultimately impact market access potential.
Evolving treatment landscapes and advances in scientific and medical innovation increase the pressure on payers, and manufacturers need to make well-planned and informed decisions about pipeline assets in that context.
We can help you examine how external factors are driving the increasing need to evaluate value potential for your assets in early pipeline. We will help you to understand how a robust value assessment framework enables your teams to align on value risks and opportunities before committing to later-stage clinical development plans.
Our consulting solutions include:
- Business development/licensing evaluation
- Portfolio planning
- Early payer risk and opportunity assessment
These services are provided by Avalere, PAI, PRMA Consulting, and Skysis – part of Fishawack Health
Request a call
